7-valent pneumococcal conjugate vaccination in england and wales is it still beneficial despite high levels of serotype replacement关于7价肺炎球菌结合疫苗接种在英格兰和威尔士还有益尽管高水平的血清型替换.pdfVIP

下载本文档

0
0
约6.11万字
约 10页
2017-09-04 发布于上海
举报
版权申诉

7-valent pneumococcal conjugate vaccination in england and wales is it still beneficial despite high levels of serotype replacement关于7价肺炎球菌结合疫苗接种在英格兰和威尔士还有益尽管高水平的血清型替换.pdf

1、本文档共10页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

7-valent pneumococcal conjugate vaccination in england and wales is it still beneficial despite high levels of serotype replacement关于7价肺炎球菌结合疫苗接种在英格兰和威尔士还有益尽管高水平的血清型替换

7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement? 1,2 2 3 4 1 5 Yoon Hong Choi *, Mark Jit , Nigel Gay , Nick Andrews , Pauline A. Waight , Alessia Melegaro , Robert George6, Elizabeth Miller1 1 Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom, 2 Modelling and Economics Unit, Health Protection Agency, London, United Kingdom, 3 Fu Consulting, Hungerford, Berkshire, United Kingdom, 4 Statistics Unit, Health Protection Agency, London, United Kingdom, 5 DONDENA Centre for Research on Social Dynamics, Bocconi University, Milan, Italy, 6 Respiratory and Systemic Infection Laboratory, Health Protection Agency, London, United Kingdom Abstract Background: The UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national vaccination program in September 2006. Previous modelling assumed that the likely impact of PCV7 on invasive pneumococcal disease (IPD) would be similar to the US experience with PCV7. However, recent surveillance data show a more rapid replacement of PCV7 IPD cases by non-PCV7 IPD cases than was seen in the US. Methods and Findings: A previous model of pneumococcal vaccination was re-parameterised using data on vaccine coverage and IPD from England and Wales between 2006 and 2009. Disease incidence was adjusted for the increasing trend in reported IPD cases prior to vaccination. Using this data we estimated that individuals carrying PCV7 serotypes have much higher protection (96%;95% CI 72%-100%) against acquisition of NVT carriage than the 15% previously estimated from US data, which leads to greater replacem